Share
A new study led by the University of Bristol in the UK has shown glaucoma could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life.
The research team led by academics at the Bristol Medical School: Translational Health Sciences tested a new approach to glaucoma treatment, which includes just a single injection that could provide patients with additional treatment options and benefits.
The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye. Using the latest gene editing technology, a gene called Aquaporin1 in the ciliary body was inactivated leading to reduced eye pressure.
Dr Colin Chu from Bristol Medical School, said: "We hope to advance towards clinical trials for this new treatment in the near future. If it's successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients”.
Academics are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.
AI is set to revolutionise the way doctors and patients interact with ophthalmic healthcare, with several published diagnostic AI models already boasting performance on par with eye specialists in the detection of diabetic retinopathy, macular degeneration, and glaucoma.
A/Prof Owen Siggs, recipient of the Glaucoma Australia ‘Quinlivan’ Research Grant in 2022 is now 18 months into his research into the Genomic Risk Stratification to improve glaucoma suspect triage in rural primary care.
Macquarie University researchers have identified a gene therapy that could help treat glaucoma, with potential applications for other neurodegenerative conditions such as Alzheimer’s disease.